Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

NCT07481734 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Associated Steatotic Liver Disease
Nonalcoholic Steatohepatitis
Hepatic Steatosis

Interventions

DRUG: Tesamorelin
DRUG: Placebo
BEHAVIORAL: Standardized lifestyle counseling

Sponsor

Hudson Biotech